Number of shares and votes in Oncopeptides

Stockholm —November 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm, ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, to...

INTERIM REPORT Q3 2020

Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (...

INTERIM REPORT Q2 2020

Summary Financial overview April 1 – June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0 M (loss: 171.9) Loss per share, before and after dilution, was SEK 6.79 (loss: 3...

Number of shares and votes in Oncopeptides

Stockholm —July 31, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to ...

Number of shares and votes in Oncopeptides

Stockholm — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the...

Number of shares and votes in Oncopeptides

Stockholm —May 29, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to ...

Interim Report Q1 2020

Summary Financial overview January 1 – March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, before and after dilution, was SEK 5.37 (...

Oncopeptides Annual Report 2019

Stockholm – April 28, 2020 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company's website. The report summarizes the company's bus...

Interim Report Q4 2019

Summary Financial overview October 1 – December 31, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 244,9 M (loss: 112.0) Loss per share, before and after dilution, was SEK 4.42 (...